BIOL368/F20:Bibliography

Week 10 Assignment Page

Search Engines

• Google Scholar
• Chrome
• Google Scholar, Google-->CDC
• Google Scholar
• LMU PubMed link
• Google Scholar
• Google Scholar
• Google Scholar
• Library OneSearch
• Google Scholar
• Google Scholar

Keywords

Warm-up exercise

• COVID-19 deaths
• COVID-19 transmission
• SARS-CoV-2 dying, getting better/worse
• COVID-19 transmission
• D614G
• civet
• long-term respiratory effects of COVID
• SARS-CoV-2 antibodies
• D614G mutation
• SARS-CoV-2 immune response
• 2019-nCoV transmission
• SARS-CoV-2 antibodies

Assigned

• Nathan: COVID-19 and immune response: 241,000
• Yaniv: COVID-19 and antibodies: 62,900
• Ian: COVID-19 and immunity: 77,500
• JT: COVID-19 and immune reaction: 104,000
• Taylor: SARS-CoV-2 and immune response: 48,800
• Nida: SARS-CoV-2 and antibodies: 48,200
• Owen: SARS-CoV-2 and immunity: 57,000
• Anna: SARS-CoV-2 and immune reaction: 97,700
• Aiden: 2019-nCoV and immune response: 25,600
• Fatimah: 2019-nCoV and antibodies: 17,400
• Kam: 2019-nCoV and immunity: 24,500
• Macie: 2019-nCoV and immune reaction: 15,500

Primary Research Articles

Group 1

1. Zhao, J., Yuan, Q., Wang, H., Liu, W., Liao, X., Su, Y., Wang, X., Yuan, Li, T. Li, J., Qian, S., Hong, C., Wang, F., Liu, Y., Wang, Z., He, Q., Li, Z., He, B., Zhang, T., Fu, Y., Ge, S., Liu, L., Zhang, J., Xia, N., Zhang, Z., & Qian, S. (2020). Antibody responses to SARS-CoV-2 in patients of novel coronavirus disease 2019. Clinical Infectious Diseases. Link: https://academic.oup.com/cid/advance-article/doi/10.1093/cid/ciaa344/5812996.
2. Jiang, S., Hillyer, C., & Du, L. (2020). Neutralizing antibodies against SARS-CoV-2 and other human coronaviruses. Trends in immunology.https://www.cell.com/trends/immunology/fulltext/S1471-4906(20)30057-0?_returnURL=https%3A%2F%2Flinkinghub.elsevier.com%2Fretrieve%2Fpii%2FS1471490620300570%3Fshowall%3Dt
3. Yuan S, Jiang SC, Li ZL. Analysis of Possible Intermediate Hosts of the New Coronavirus SARS-CoV-2. Front Vet Sci. 2020 Jun 9;7:379. doi: 10.3389/fvets.2020.00379. PMID: 32582786; PMCID: PMC7297130.
   • found here
4. Rogers, T. F., Zhao, F., Huang, D., Beutler, N., Burns, A., He, W. T., ... & Yang, L. (2020). Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model. Science, 369(6506), 956-963. https://science.sciencemag.org/content/369/6506/956.full
5. Imai, M., Iwatsuki-Horimoto, K., Hatta, M., Loeber, S., Halfmann, P. J., Nakajima, N., ... & Yamada, S. (2020). Syrian hamsters as a small animal model for SARS-CoV-2 infection and countermeasure development. Proceedings of the National Academy of Sciences, 117(28), 16587-16595. https://www.pnas.org/content/pnas/117/28/16587.full.pdf

Group 2

• Immune Response, Inflammation, and the Clinical Spectrum of COVID-19
  • García, L. F. (2020). Immune response, inflammation, and the clinical spectrum of COVID-19. Frontiers in immunology, 11, 1441.
    • Link: https://www.frontiersin.org/articles/10.3389/fimmu.2020.01441/full
• A SARS-CoV-2 infection model in mice demonstrates protection by neutralizing antibodies
  • Hassan, A. O., Case, J. B., Winkler, E. S., Thackray, L. B., Kafai, N. M., Bailey, A. L., ... & Turner, J. S. (2020). A SARS-CoV-2 infection model in mice demonstrates protection by neutralizing antibodies. Cell, 182(3), 744-753.
  • https://www.cell.com/cell/pdf/S0092-8674(20)30742-X.pdf
• Xu, X., Han, M., Li, T., Sun, W., Wang, D., Fu, B., ... & Zhang, X. (2020). Effective treatment of severe COVID-19 patients with tocilizumab. Proceedings of the National Academy of Sciences, 117(20), 10970-10975.

Group 3

Korber, B., Fischer, W. M., Gnanakaran, S., Yoon, H., Theiler, J., Abfalterer, W., ... & Hastie, K. M. (2020). Tracking changes in SARS-CoV-2 Spike: evidence that D614G increases infectivity of the COVID-19 virus. Cell, 182(4), 812-827.

• Korber, B., Fischer, W. M., Gnanakaran, S., Yoon, H., Theiler, J., Abfalterer, W., ... & Hastie, K. M. (2020). Tracking changes in SARS-CoV-2 Spike: evidence that D614G increases infectivity of the COVID-19 virus. Cell, 182(4), 812-827.

Ian R. Wright (talk) 08:58, 12 November 2020 (PST)

• Ling, Y., Xu, S. B., Lin, Y. X., Tian, D., Zhu, Z. Q., Dai, F. H., ... & Hu, B. J. (2020). Persistence and clearance of viral RNA in 2019 novel coronavirus disease rehabilitation patients. Chinese medical journal.

Ian R. Wright (talk) 15:54, 5 November 2020 (PST)

• Zhao, J., Yuan, Q., Wang, H., Liu, W., Liao, X., Su, Y., Wang, X., Yuan, Li, T. Li, J., Qian, S., Hong, C., Wang, F., Liu, Y., Wang, Z., He, Q., Li, Z., He, B., Zhang, T., Fu, Y., Ge, S., Liu, L., Zhang, J., Xia, N., Zhang, Z., & Qian, S. (2020). Antibody responses to SARS-CoV-2 in patients of novel coronavirus disease 2019. Clinical Infectious Diseases. Link: https://academic.oup.com/cid/advance-article/doi/10.1093/cid/ciaa344/5812996. Anna Horvath (talk) 15:56, 5 November 2020 (PST)

• Wu, J. L., Tseng, W. P., Lin, C. H., Lee, T. F., Chung, M. Y., Huang, C. H., ... & Chen, S. C. (2020). Four point-of-care lateral flow immunoassays for diagnosis of COVID-19 and for assessing dynamics of antibody responses to SARS-CoV-2. Journal of Infection, 81(3), 435-442.

[1] Falghane (talk) 15:59, 5 November 2020 (PST)

• Netea MG, Giamarellos-Bourboulis EJ, Domínguez-Andrés J, Curtis N, van Crevel R, van de Veerdonk FL, Bonten M. Trained Immunity: a Tool for Reducing Susceptibility to and the Severity of SARS-CoV-2 Infection. Cell. 2020 May 28;181(5):969-977. doi: 10.1016/j.cell.2020.04.042. Epub 2020 May 4. PMID: 32437659; PMCID: PMC7196902. Owen R. Dailey (talk) 16:00, 5 November 2020 (PST)

• Ogawa J, Zhu W, Tonnu N, et al. The D614G mutation in the SARS-CoV2 Spike protein increases infectivity in an ACE2 receptor dependent manner. Preprint. bioRxiv. 2020;2020.07.21.214932. Published 2020 Jul 22. doi:10.1101/2020.07.21.214932 Owen R. Dailey (talk) 16:00, 5 November 2020 (PST)

• Ju, B., Zhang, Q., Ge, J., Wang, R., Sun, J., Ge, X., Tang, X. (2020). Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature, 584(7819), 115-119. https://doi.org/10.1038/s41586-020-2380-z. Link: https://www.nature.com/articles/s41586-020-2380-z. Anna Horvath (talk) 16:02, 5 November 2020 (PST)

• Thibaudin, M., Fumet, J.D., Bon, M., Hampe, L., Limagne, E., Ghiringhelli, F. (2020). Immunological Features of Coronavirus Disease 2019 in Patients with Cancer. European Journal of Cancer. Link: http://apps.webofknowledge.com.electra.lmu.edu/full_record.do?product=WOS&search_mode=GeneralSearch&qid=1&SID=5BS29A7o7askyd9nt4r&page=1&doc=6. Taylor Makela (talk) 16:05, 5 November 2020 (PST)

• Hassan, A. O., Case, J. B., Winkler, E. S., Thackray, L. B., Kafai, N. M., Bailey, A. L., ... & Turner, J. S. (2020). A SARS-CoV-2 infection model in mice demonstrates protection by neutralizing antibodies. Cell, 182(3), 744-753. https://www.cell.com/cell/pdf/S0092-8674(20)30742-X.pdf Jcorrey (talk) 16:06, 5 November 2020 (PST)

• Seroprevalence of COVID-19 antibodies in the cleaning and oncological staff of a municipal clinic
  • Epstude, J., & Harsch, I. A. (2020). Seroprevalence of COVID-19 antibodies in the cleaning and oncological staff of a municipal clinic. GMS hygiene and infection control, 15.

Yaniv Maddahi (talk) 16:06, 5 November 2020 (PST)

• Diagnosing COVID-19 in the Emergency Department: A Scoping Review of Clinical Examinations, Laboratory Tests, Imaging Accuracy, and Biases
  • Carpenter, C. R., Mudd, P. A., West, C. P., Wilber, E., & Wilber, S. T. (2020). Diagnosing COVID‐19 in the Emergency Department: A Scoping Review of Clinical Examinations, Laboratory Tests, Imaging Accuracy, and Biases. Academic Emergency Medicine, 27(8), 653-670.

Yaniv Maddahi (talk) 16:19, 5 November 2020 (PST)

• Ju, B., Zhang, Q., Ge, J., Wang, R., Sun, J., Ge, X., ... & Tang, X. (2020). Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature, 584(7819), 115-119.https://www.nature.com/articles/s41586-020-2380-z Nidapatel (talk) 16:08, 5 November 2020 (PST)

• Unanswered questions on immune response and pathogenesis.
  • Maggi, E., Canonica, G. W., & Moretta, L. (2020). COVID-19: Unanswered questions on immune response and pathogenesis. The Journal of allergy and clinical immunology, 146(1), 18–22.
• Community-based interventions for preventing COVID-19 transmission in low-and middle-income countries: A systematic review
  • Chisale, M. R., Ramazanu, S., Wu, J. T. S., Sinyiza, F. W., Bvumbwe, T., Nyambalo, B., & Mbakaya, B. C. (2020). Community-based interventions for preventing COVID-19 transmission in low-and middle-income countries: A systematic review.

Nathan R. Beshai (talk) 16:12, 5 November 2020 (PST)

• Varchetta, S., Mele, D., Oliviero, B., Mantovani, S., Ludovisi, S., Cerino, A., ... & Roda, S. (2020). Unique immunological profile in patients with COVID-19. Cellular & Molecular Immunology, 1-9.
• http://apps.webofknowledge.com.electra.lmu.edu/full_record.do?product=WOS&search_mode=GeneralSearch&qid=13&SID=7EXpRd2UtKtzGs9F5zx&page=1&doc=20

Kam Taghizadeh (talk) 16:15, 5 November 2020 (PST)

• Xu, X., Han, M., Li, T., Sun, W., Wang, D., Fu, B., ... & Zhang, X. (2020). Effective treatment of severe COVID-19 patients with tocilizumab. Proceedings of the National Academy of Sciences, 117(20), 10970-10975. (Macie Duran (talk) 20:56, 9 November 2020 (PST))

Review Articles

• Cheng VC, Lau SK, Woo PC, Yuen KY. Severe acute respiratory syndrome coronavirus as an agent of emerging and reemerging infection. Clin Microbiol Rev. 2007 Oct;20(4):660-94. doi: 10.1128/CMR.00023-07. PMID: 17934078; PMCID: PMC2176051.
  • found here
  • Aiden Burnett (talk) 15:55, 5 November 2020 (PST)

• Zhao J, Cui W, Tian BP. The Potential Intermediate Hosts for SARS-CoV-2. Front Microbiol. 2020 Sep 30;11:580137. doi: 10.3389/fmicb.2020.580137. PMID: 33101254; PMCID: PMC7554366.
  • Found here
  • Aiden Burnett (talk) 16:07, 5 November 2020 (PST)

• Yuan S, Jiang SC, Li ZL. Analysis of Possible Intermediate Hosts of the New Coronavirus SARS-CoV-2. Front Vet Sci. 2020 Jun 9;7:379. doi: 10.3389/fvets.2020.00379. PMID: 32582786; PMCID: PMC7297130.
  • found here
  • Aiden Burnett (talk) 16:10, 5 November 2020 (PST)

• Deeks JJ, Dinnes J, Takwoingi Y, Davenport C, Spijker R, Taylor-Phillips S, Adriano A, Beese S, Dretzke J, Ferrante di Ruffano L, Harris IM, Price MJ, Dittrich S, Emperador D, Hooft L, Leeflang MMG, Van den Bruel A. (2020). Antibody tests for identification of current and past infection with SARS‐CoV‐2. Cochrane Database of Systematic Reviews 2020, Issue 6. Art. No.: CD013652. DOI: 10.1002/14651858.CD013652. Link: https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD013652/abstract Anna Horvath (talk) 15:53, 5 November 2020 (PST)

• Jiang, S., Hillyer, C., & Du, L. (2020). Neutralizing antibodies against SARS-CoV-2 and other human coronaviruses. Trends in immunology.https://www.cell.com/trends/immunology/fulltext/S1471-4906(20)30057-0?_returnURL=https%3A%2F%2Flinkinghub.elsevier.com%2Fretrieve%2Fpii%2FS1471490620300570%3Fshowall%3Dtrue Nidapatel (talk) 16:00, 5 November 2020 (PST)

• Immune Response, Inflammation, and the Clinical Spectrum of COVID-19
  • García, L. F. (2020). Immune response, inflammation, and the clinical spectrum of COVID-19. Frontiers in immunology, 11, 1441.

Yaniv Maddahi (talk) 16:02, 5 November 2020 (PST)

• Elhabyan, A., El Yaacoub, S., Sanad, E., Mohamed, A., Elhabyan, A., & Dinu, V. (2020). The role of Host Genetics in susceptibility to severe viral infections in humans and INSIGHTS into host genetics of severe COVID-19: A systematic review. Virus Research, 198163.
  • http://apps.webofknowledge.com.electra.lmu.edu/full_record.do?product=WOS&search_mode=GeneralSearch&qid=7&SID=7EXpRd2UtKtzGs9F5zx&page=1&doc=1

Kam Taghizadeh (talk) 16:04, 5 November 2020 (PST)

• Nicola, M., Alsafi, Z., Sohrabi, C., Kerwan, A., Al-Jabir, A., Iosifidis, C., ... & Agha, R. (2020). The socio-economic implications of the coronavirus and COVID-19 pandemic: a review. International Journal of Surgery.
  • https://www-sciencedirect-com.electra.lmu.edu/science/article/pii/S1743919120303162?via%3Dihub
• Kampf, G., Todt, D., Pfaender, S., & Steinmann, E. (2020). Persistence of coronaviruses on inanimate surfaces and their inactivation with biocidal agents. Journal of Hospital Infection, 104(3), 246-251.
  • https://www.journalofhospitalinfection.com/article/S0195-6701(20)30046-3/pdf

Jcorrey (talk) 16:07, 5 November 2020 (PST)

• The Impact of Mutations in SARS-CoV-2 Spike on Viral Infectivity and Antigenicity, [2]Falghane (talk)

• Immune Response, Inflammation, and the Clinical Spectrum of COVID-19.
  • García LF. Immune Response, Inflammation, and the Clinical Spectrum of COVID-19. Front Immunol. 2020 Jun 16;11:1441. doi: 10.3389/fimmu.2020.01441. PMID: 32612615; PMCID: PMC7308593.

Nathan R. Beshai (talk) 16:14, 5 November 2020 (PST)

• Wang, H., Li, X., Li, T., Zhang, S., Wang, L., Wu, X., & Liu, J. (2020). The genetic sequence, origin, and diagnosis of SARS-CoV-2. European Journal of Clinical Microbiology & Infectious Diseases, 1. (Macie Duran (talk) 20:57, 9 November 2020 (PST))

• Kumar, A., Prasoon, P., Kumari, C., Pareek, V., Faiq, M. A., Narayan, R. K., ... & Kant, K. (2020). SARS‐CoV‐2 specific virulence factors in COVID‐19. Journal of Medical Virology.

Ian R. Wright (talk) 08:57, 12 November 2020 (PST)

• Ovsyannikova IG, Haralambieva IH, Crooke SN, Poland GA, Kennedy RB. The role of host genetics in the immune response to SARS-CoV-2 and COVID-19 susceptibility and severity. Immunol Rev. 2020 Jul;296(1):205-219. doi: 10.1111/imr.12897. Epub 2020 Jul 13. PMID: 32658335; PMCID: PMC7404857.
  • Link: https://pubmed.ncbi.nlm.nih.gov/32658335/

Taylor Makela (talk) 12:05, 12 November 2020 (PST)

Other Articles

• Mohamed-Hussein, A. A. R., Makhlouf, N. A., Yassa, H., & Makhlouf, H. A. (2020). Corona-Like Illness: Did we get it before WHO Announcement of the Disease? A Cross-sectional Survey. Electron J Gen Med. 2020; 17 (6): em258.http://apps.webofknowledge.com.electra.lmu.edu/full_record.do?product=WOS&search_mode=GeneralSearch&qid=1&SID=7DZDTqY4ARKQyiWxudh&page=1&doc=4 Nidapatel (talk) 15:51, 5 November 2020 (PST)